Marianne P. Allen

Array ( [id] => 17362674 [patent_doc_number] => 11229682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-25 [patent_title] => Methods of treatment for kidney disease [patent_app_type] => utility [patent_app_number] => 16/496117 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 4 [patent_no_of_words] => 4307 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16389649 [patent_doc_number] => 20200330590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCTION OF IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 16/498063 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21926 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314275 [patent_doc_number] => 20180208674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => COMBINATIONS OF EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING ANTIBODIES FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/935010 [patent_app_country] => US [patent_app_date] => 2018-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11955 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15935010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986469 [patent_doc_number] => 20190062392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => METHODS FOR TREATING FATTY LIVER DISEASE [patent_app_type] => utility [patent_app_number] => 15/925556 [patent_app_country] => US [patent_app_date] => 2018-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15925556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13955589 [patent_doc_number] => 20190054138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING HGF/MET [patent_app_type] => utility [patent_app_number] => 15/921827 [patent_app_country] => US [patent_app_date] => 2018-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15921827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15559859 [patent_doc_number] => 20200064341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => TARGET DETECTION USING A MONOVALENT ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/492987 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16492987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206589 [patent_doc_number] => 20200239579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ANTIBODIES AGAINST PD-L1 [patent_app_type] => utility [patent_app_number] => 16/491464 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12904729 [patent_doc_number] => 20180193418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => MUTATED FIBROBLAST GROWTH FACTOR (FGF) 1 AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/910332 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910332 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16770883 [patent_doc_number] => 10981972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => Endoglin polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 15/908644 [patent_app_country] => US [patent_app_date] => 2018-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 41 [patent_no_of_words] => 23939 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209785 [patent_doc_number] => 20190367579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => TIGIT- AND LIGHT-BASED CHIMERIC PROTEINS [patent_app_type] => utility [patent_app_number] => 16/484850 [patent_app_country] => US [patent_app_date] => 2018-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484850 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14324069 [patent_doc_number] => 10293027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Methods for treating metabolic disorders using FGF [patent_app_type] => utility [patent_app_number] => 15/904614 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 59 [patent_no_of_words] => 14878 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15904614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12885079 [patent_doc_number] => 20180186868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => ANTIBODY AGAINST HUMAN NRG1 PROTEIN [patent_app_type] => utility [patent_app_number] => 15/900846 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15900846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963149 [patent_doc_number] => 20200165326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => IMMUNOCONJUGATES WITH OPTIMIZED LINKERS AND ORIENTATION [patent_app_type] => utility [patent_app_number] => 16/487991 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12950 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15816517 [patent_doc_number] => 10633424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Chimeric fibroblast growth factor 19 proteins and methods of use [patent_app_type] => utility [patent_app_number] => 15/896469 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 40359 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15896469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17697123 [patent_doc_number] => 11370834 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => Anti-VEGFR-2 monoclonal antibody [patent_app_type] => utility [patent_app_number] => 16/487833 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 3671 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16141453 [patent_doc_number] => 10703788 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-07 [patent_title] => Chimeric fibroblast growth factor 21 proteins and methods of use [patent_app_type] => utility [patent_app_number] => 15/895770 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 42486 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590594 [patent_doc_number] => 10899844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => FGF21 mimetic antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/890302 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 46872 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15321101 [patent_doc_number] => 20200000880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => FGF21 COMPOSITIONS FOR TREATMENT OR PREVENTION OF NEOVASCULARIZATION OF THE EYE AND METHODS THEREFOR [patent_app_type] => utility [patent_app_number] => 16/483034 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147793 [patent_doc_number] => 20190352374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => NOVEL IGFR_LIKE 2 RECEPTOR AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/481781 [patent_app_country] => US [patent_app_date] => 2018-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368326 [patent_doc_number] => 12060396 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis [patent_app_type] => utility [patent_app_number] => 16/481128 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 40 [patent_no_of_words] => 9665 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16481128 [rel_patent_id] =>[rel_patent_doc_number] =>)